

## References

Provided by: Hajime Uno, Ph.D.  
Dana-Farber Cancer Institute/Harvard Medical School  
Methods: Mind the Gap  
June 25, 2024

### Key references for the presentations:

Irwin JO. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. *The Journal of Hygiene*, 1949; 47(2), 188.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *Journal of the American statistical association*, 1958;53, 457–481.

Gill RD. Censoring and stochastic integrals. Mathematisch Centrum. 1980.

Karrison T. Restricted mean life with adjustment for covariates. *Journal of the American Statistical Association*, 1987; 82(400), 1169–1176.

Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York: John Wiley & Sons; 1991.

Karrison TG. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups—Interpretation and power considerations. *Controlled Clinical Trials*. 1997;18(2), 151–167.

Zucker DM. Restricted Mean Life with Covariates: Modification and Extension of a Useful Survival Analysis Method. *Journal of the American Statistical Association*, 1998;93(442), 702–709.

Zhao L, Tian L, Uno H, et al. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. *Clin Trials*. 2012;9(5):570-577.

Royston P, Parmar M. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. *Stat Med* 2011;30, 2409–2421.

Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. *BMC Med Res Methodol*. 2013;13(1):152.

Motzer R J, Tannir N M, McDermott D F, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med*. 2018;378(14):1277–1290.

Uno H, Horiguchi M, Hassett MJ. Statistical test/estimation methods used in contemporary phase III cancer randomized controlled trials with time-to-event outcomes. *Oncologist*. 2020;25(2):91–93.

Cox DR. Regression models and life-tables. *J R Stat Soc Series B Stat Methodol*. 1972;34(2):187–220.

Cox DR. Partial likelihood. *Biometrika*. 1975;62(2):269–276.

Hernán Miguel A. The hazards of hazard ratios. *Epidemiology*. 2010;21(1):13–15.

Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014;32(22):2380–2385.

Uno H, Wittes J, Fu H, et al. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. *Ann Intern Med*. 2015;163(2):127–134.

Horiguchi M, Hassett MJ, Uno H. How do the accrual pattern and follow-up duration affect the hazard ratio estimate when the proportional hazards assumption is violated? *Oncologist*. 2019;24(7):867–871.

Cobos-Carbo Albert, Augustovski Federico. CONSORT 2010 Declaration: updated guideline for reporting parallel group randomised trials. *Med. Clin*. 2011;137(5):213–215.

Annals of Internal Medicine. Information for Authors: General Statistical Guidance (Section 4: Measures of Effect and Risk). Accessed Mar. 14, 2024.

<https://www.acpjournals.org/journal/aim/authors/statistical-guidance>.

Orkaby AR, Rich MW, Sun R, et al. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. *Journal of the American Geriatrics Society* 2018; 66(10), 1987–1991.

Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1. Erratum in: *Lancet*. 2009 Nov 21-2009 Nov 27;(9703):1744. PMID: 13678868.

Tian L, Zhao L, Wei LJ. Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. *Biostatistics*. 2014;15(2):222–233.

Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations. *Lifetime Data Analysis*, 2004; 10(4), 335–350.

Uno H, Tian L, Horiguchi M, et al. survRM2: Comparing Restricted Mean Survival Time. R package version 1.0-2. 2017; Available from: <https://CRAN.R-project.org/package=survRM2>

Cronin A, Tian L, Uno H. strms2 and strms2pw: New commands to compare survival curves using the restricted mean survival time. *Stata J*. 2016;16(3):702–716.

Guo C, Liang Y. Analyzing Restricted Mean Survival Time Using SAS/STAT. Published online 2019. Paper SAS3013-2019  
<https://www.semanticscholar.org/paper/43995ccd2532e0ad50ec872b70e9c67bb32faec2>

#### **Other important references in this field:**

Eaton A, Therneau T, Le-Rademacher J. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations. *Clin Trials*. Published online February 17, 2020:1740774520905563.

Horiguchi M, Uno H. SSRMST: Sample size calculation using restricted mean survival time. 2017. Available from: <https://cran.r-project.org/web/packages/SSRMST/index.html>.

Tian L, Jin H, Uno H, Lu Y, Huang B, Anderson KM, Wei LJ. On the empirical choice of the time window for restricted mean survival time. *Biometrics*. 2020;76(4):1157–1166.

Tian L, Jiang F, Hasegawa T, et al. Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study. *Stat. Med.* 2019;38(6):917–932.

Sun R, McCaw Z, Tian L, et al. Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. *J Immuno ther Cancer*. 2021;9(11).

Murray S, Tsiatis AA. Sequential methods for comparing years of life saved in the two-sample censored data problem. *Biometrics* 1999 Jan 1;55(4):1085–1092

Lu Y, Tian L. Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials. *Statistics in Biopharmaceutical Research*. 2020. p. 1–14.

Tian L, Fu H, Ruberg SJ, Uno H, Wei L-J. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. *Biometrics*. 2018;74(2):694–702.

Horiguchi M, Hassett MJ, Uno H. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. *Clinical Trials* 2020: 17(6), 597–606.

Conner SC, Sullivan LM, Benjamin EJ, et al. Adjusted restricted mean survival times in observational studies. *Stat Med*. 2019;38(20):3832–3860.

Zhang M, Schaubel DE. Estimating differences in restricted mean lifetime using observational data subject to dependent censoring. *Biometrics*. 2011 Sep;67(3):740-9.

Zhang M, Schaubel DE. Contrasting treatment-specific survival using double-robust estimators. *Stat Med*. 2012 Dec 30;31(30):4255-68.

Zhang M, Schaubel DE. Double-robust semiparametric estimator for differences in restricted mean lifetimes in observational studies. *Biometrics*. 2012 Dec;68(4):999-1009.

Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. *Stat Med*. 2023 May 10;42(10):1461-1479.

Shu D, Mukhopadhyay S, Uno H, et al. Multiply robust causal inference of the restricted mean survival time difference. *Stat Methods Med Res*. 2023 Dec;32(12):2386-2404.

Zhao L, Tian L, Claggett B, et al. Estimating treatment effect with clinical interpretation from a comparative clinical trial with an end point subject to competing risks. *JAMA cardiology*. 2018;3(4), pp.357-358.

Calkins KL, Canan CE, Moore RD, Lesko CR, Lau B. An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use. *BMC Med Res Methodol*. 2018;18(1):27.

Lyu J, Hou Y, Chen Z. The use of restricted mean time lost under competing risks data. *BMC Med Res Methodol*. 2020;20(1):197.

Claggett B, Tian L, Fu H, et al. 2018. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. *Statistics in Medicine*, 37(25), pp.3589-3598.

Chen X, Harhay MO, Li F. Clustered restricted mean survival time regression. *Biom J*. 2023 Aug;65(6):e2200002.

Vilain-Abraham FL, Tavernier E, Dantan E, Desmée S, Caille A. Restricted mean survival time to estimate an intervention effect in a cluster randomized trial. *Stat Methods Med Res*. 2023 Oct;32(10):2016-2032.

Horiguchi M, Tian L, Uno H, et al. Quantification of long-term survival benefit in a comparative oncology clinical study. *JAMA oncology*. 2018;4(6):881–882.

Paukner M, Chappell R. Window mean survival time. *Statistics in Medicine*, 2021;40(25), 5521–5533.

Horiguchi M, Tian L, Uno H. On assessing survival benefit of immunotherapy using long-term restricted mean survival time. *Statistics in Medicine*. 2023, 1–17.

Horiguchi M, Tian L, Uno H. survRM2adapt: Flexible and Coherent Test/Estimation Procedure Based on Restricted Mean Survival Times. R package version 1.1.0, 2023.

Available from: <https://CRAN.R-project.org/package=survRM2adapt>

A'Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? *J Clin Oncol*. 2016;34(28):3474–3476.

Chappell R, Zhu X. Describing differences in survival curves. *JAMA oncol*. 2016;2(7):906–907.

Uno H, Claggett B, Tian L, et al. Adding a new analytical procedure with clinical interpretation in the toolbox of survival analysis. *Ann Oncol*. 2018;29(5):1092-1094.

Uno H, Schrag D, Kim DH, et al. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. *JNCI Cancer Spectr*. 2019;3(4):kz058.

Uno H, Tian L. Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials? *J Clin Oncol*. 2020;38(17):2000-2001.

Huang B, Tian L, Talukder E, et al. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. *JAMA Oncol*. 2018;4(6):874-876.

Huang B, Tian L, McCaw ZR, et al. Analysis of response data for assessing treatment effects in comparative clinical studies. *Annals of internal medicine*, 2020;173(5), pp.368-374.

#### **Other references used for this presentation (not directly related to RMST)**

Guyot Patricia, Ades AE, Ouwens Mario JNM, Welton Nicky J. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC medical research methodology*. 2012;12:1–13.

Gilbert PB, Wei LJ, Kosorok MR, Clemens JD. Simultaneous Inferences on the Contrast of Two Hazard Functions with Censored Observations. *Biometrics* 2002;58(4):773-780.

Lin DY, Wei LJ, Ying Z. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. *Biometrika*. 1993;80(3):557-572.

gof R package: <https://cran.r-project.org/src/contrib/Archive/gof/>